Review
doi: 10.1158/1535-7163.MCT-09-1186.
Epub 2010 May 4.
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Affiliations
- PMID: 20442309
- DOI: 10.1158/1535-7163.MCT-09-1186
Item in Clipboard
Review
Metformin in cancer therapy: a new perspective for an old antidiabetic drug?
Mol Cancer Ther.
2010 May.
Abstract
Metformin is the most widely used antidiabetic drug in the world, and there is increasing evidence of a potential efficacy of this agent as an anticancer drug. First, epidemiological studies show a decrease in cancer incidence in metformin-treated patients. Second, metformin decreases insulin resistance and indirectly reduces insulin level, a beneficial effect because insulin promotes cancer cell growth. Third, several reports outline a direct inhibitory effect of metformin on cancer cell growth and an antitumoral action. Finally, metformin activates the AMP activated protein kinase (AMPK) pathway, a major sensor of the energetic status of the cell, which has been proposed as a promising therapeutic target in cancer.
Similar articles
-
Molecular targets of metformin antitumor action.Pharmacol Rep. 2016 Oct;68(5):918-25. doi: 10.1016/j.pharep.2016.04.021. Epub 2016 May 9. Pharmacol Rep. 2016. PMID: 27362768 Review.
-
Metformin: its emerging role in oncology.Hormones (Athens). 2011 Jan-Mar;10(1):5-15. doi: 10.14310/horm.2002.1288. Hormones (Athens). 2011. PMID: 21349801 Review.
-
The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy.Ann Oncol. 2009 Mar;20(3):592-5. doi: 10.1093/annonc/mdn758. Epub 2009 Jan 19. Ann Oncol. 2009. PMID: 19153119 No abstract available.
-
Metformin prevents tobacco carcinogen--induced lung tumorigenesis.Cancer Prev Res (Phila). 2010 Sep;3(9):1066-76. doi: 10.1158/1940-6207.CAPR-10-0055. Epub 2010 Sep 1. Cancer Prev Res (Phila). 2010. PMID: 20810672 Free PMC article.
-
Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth.Clin Cancer Res. 2011 Jun 15;17(12):3993-4005. doi: 10.1158/1078-0432.CCR-10-2243. Epub 2011 May 4. Clin Cancer Res. 2011. PMID: 21543517
Cited by
-
Metformin prevents the development of oral squamous cell carcinomas from carcinogen-induced premalignant lesions.Cancer Prev Res (Phila). 2012 Apr;5(4):562-73. doi: 10.1158/1940-6207.CAPR-11-0502. Epub 2012 Mar 31. Cancer Prev Res (Phila). 2012. PMID: 22467081 Free PMC article.
-
Phenylethynylbenzyl-modified biguanides inhibit pancreatic cancer tumor growth.Sci Rep. 2021 May 10;11(1):9854. doi: 10.1038/s41598-021-87993-3. Sci Rep. 2021. PMID: 33972583 Free PMC article.
-
Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells.Endocr Relat Cancer. 2012 May 24;19(3):447-56. doi: 10.1530/ERC-12-0046. Print 2012 Jun. Endocr Relat Cancer. 2012. PMID: 22389381
-
Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway.Photochem Photobiol. 2012 Sep-Oct;88(5):1149-56. doi: 10.1111/j.1751-1097.2012.01165.x. Epub 2012 Jun 1. Photochem Photobiol. 2012. PMID: 22540890 Free PMC article.
-
Metformin inhibits pancreatic cancer cell and tumor growth and downregulates Sp transcription factors.Carcinogenesis. 2013 Dec;34(12):2870-9. doi: 10.1093/carcin/bgt231. Epub 2013 Jun 26. Carcinogenesis. 2013. PMID: 23803693 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
